However, at the on-treatment time point (cycle 2), both CD8 and PD-1 were associated with ORR, suggesting a potential change in tumor immune microenvironment in patients who attained a partial response (PR; linear model p = 0.01 and 0.002, covariate p = 4.6 × 10−4 and 7.3 × 10−5, respectively; Fig. 2A, B). The gene discussed is PDCD1; the disease is neoplasm.